Get the Stockscreener App
0.748
1.77%
0.013
Avenue Therapeutics Inc stock is traded at $0.748, with a volume of 916.
It is up +1.77% in the last 24 hours and up +1.77% over the past month.
See More
Previous Close:
$0.735
Open:
$0.748
24h Volume:
916
Relative Volume:
1.68
Market Cap:
$N/A
Revenue:
-
Net Income/Loss:
$-10.38M
P/E Ratio:
-0.1963
EPS:
-3.81
Net Cash Flow:
$-12.45M
1W Performance:
+1.77%
1M Performance:
+1.77%
6M Performance:
-83.79%
1Y Performance:
-96.88%
1-Day Range:
$0.748
$0.748
1-Week Range:
$0.748
$0.748
52-Week Range:
$0.5231
$0.748
Avenue Therapeutics Inc Stock (ATXI) Company Profile
Name
Avenue Therapeutics Inc
Sector
Industry
Phone
-
Address
-
Compare ATXI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATXI
Avenue Therapeutics Inc
|
0.748 | 0 | 0 | -10.38M | -12.45M | -3.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Avenue Therapeutics Inc Stock (ATXI) Latest News
Kyverna Therapeutics (NASDAQ:KYTX) Upgraded to "Hold" at Wall Street Zen - MarketBeat
Is PTC Therapeutics Inc. stock a defensive play in 20252025 Price Targets & Smart Investment Allocation Tips - ulpravda.ru
PTC Therapeutics (NASDAQ:PTCT) Upgraded to Buy at Wall Street Zen - MarketBeat
Capricor Therapeutics (NASDAQ:CAPR) Upgraded at Wall Street Zen - MarketBeat
Avenue Therapeutics (ATXI) investors reelect six directors and ratify KPMG for 2025 - Stock Titan
Avenue Therapeutics shareholders elect directors, ratify KPMG auditor - TipRanks
Axsome Therapeutics shares gain 1.4% premarket after FDA grants priority review for co's Alzheimer's agitation drug - marketscreener.com
FDA supports Axsome’s NDA submission for narcolepsy drug AXS-12 By Investing.com - Investing.com Australia
ATXI: All directors were elected and KPMG LLP was ratified as auditor for 2025 - TradingView — Track All Markets
ATXI: All director nominees were elected and KPMG LLP was ratified as auditor for 2025 - TradingView — Track All Markets
Dyne Therapeutics (NASDAQ:DYN) Stock Rating Lowered by Wall Street Zen - MarketBeat
vTv Therapeutics (NASDAQ:VTVT) Upgraded at Wall Street Zen - MarketBeat
NexImmune (NASDAQ:NEXI) versus Avenue Therapeutics (NASDAQ:ATXI) Head-To-Head Comparison - Defense World
Avenue Therapeutics, Inc.Common Stock (NQ: ATXI - FinancialContent
Form 424B3 Ovid Therapeutics Inc. - StreetInsider
Will Neumora Therapeutics Inc. stock benefit from AI adoptionOil Prices & Weekly Setup with High ROI Potential - Улправда
Axsome Therapeutics stock hits all-time high at 152.98 USD - Investing.com
Axsome Therapeutics stock hits all-time high at 152.98 USD By Investing.com - Investing.com Australia
Axsome Therapeutics (AXSM) Receives a Buy from Wells Fargo - The Globe and Mail
Axsome Therapeutics (AXSM) Gets a Buy from Jefferies - The Globe and Mail
Avenue Therapeutics (ATXI) plans resale of 731,061 warrant-linked shares - Stock Titan
[RW] AVENUE THERAPEUTICS, INC. SEC Filing - Stock Titan
Spero Therapeutics (NASDAQ:SPRO) Upgraded to "Buy" at Wall Street Zen - MarketBeat
TG Therapeutics (NASDAQ:TGTX) Rating Increased to Buy at Wall Street Zen - MarketBeat
RBC Capital Sticks to Its Buy Rating for Axsome Therapeutics (AXSM) - The Globe and Mail
Sionna Therapeutics (NASDAQ:SION) Upgraded at Wall Street Zen - MarketBeat
Axsome Confident On Regulatory, Commercial Outlook for Alzheimer's Agitation Drug Candidate, RBC Says - marketscreener.com
Vera Therapeutics (VERA) Stock Outlook: December 11, 2025 Update on Public Offering, Atacicept BLA and Wall Street Targets - ts2.tech
Dyne Therapeutics Announces Pricing of Upsized $350.0 Million Public Offering of Common Stock - GlobeNewswire
Avenue Therapeutics Inc. (ATXI) Stock Price | Live Quotes & Charts | OTO - StocksToTrade
Spero Therapeutics (NASDAQ:SPRO) Stock Rating Lowered by Wall Street Zen - MarketBeat
Rapport Therapeutics (NASDAQ:RAPP) Downgraded to Sell Rating by Wall Street Zen - MarketBeat
Avenue Therapeutics (NASDAQ: ATXI) 2025 proxy on director elections, KPMG audit and Fortress control - Stock Titan
Wall Street Analysts Think Mineralys Therapeutics, Inc. (MLYS) Could Surge 27.55%: Read This Before Placing a Bet - WV News
Axsome therapeutics CEO Tabuteau sells $11.6 million in shares By Investing.com - Investing.com India
Axsome therapeutics CEO Tabuteau sells $11.6 million in shares - Investing.com
Minerva jumps on phase III funding, leading neuro stocks - BioWorld MedTech
Wall Street Analysts Believe Enliven Therapeutics, Inc. (ELVN) Could Rally 101.26%: Here's is How to Trade - WV News
Akebia Therapeutics (NASDAQ:AKBA) Downgraded by Wall Street Zen to "Buy" - MarketBeat
Protagenic Therapeutics Announces Receipt of Nasdaq Non-Compliance Notice - USA Today
Esperion Therapeutics Stock Hits Near 1-Year High As Wall Street Sees Strong Risk-Reward Play On Demand For Cholesterol Drug - Stocktwits
Avenue Therapeutics Leads Six-Month Stock Performance with 267.29% Return - Markets Mojo
Axsome Therapeutics stock reaches all-time high of 152.94 USD By Investing.com - Investing.com Australia
Axsome Therapeutics stock reaches all-time high of 152.94 USD - Investing.com
Avenue Therapeutics Leads Six-Month Stock Performance with 253.98% Return - Markets Mojo
Avenue Therapeutics Leads Six-Month Stock Performance with 257.7% Return - Markets Mojo
Village Farms International Leads with 276.7% Return in Recent Six Months - Markets Mojo
Axsome Therapeutics to Participate in Upcoming Investor Conferences - marketscreener.com
Avenue Therapeutics Announces 2025 Annual Meeting Date - The Globe and Mail
[8-K] AVENUE THERAPEUTICS, INC. Reports Material Event | ATXI SEC FilingForm 8-K - Stock Titan
Village Farms International Leads with 282% Return in Recent Performance Surge - Markets Mojo
Avenue Therapeutics Inc Stock (ATXI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.90%
Cap:
|
Volume (24h):